In a single-center, open-label, non-randomized, noncontrolled conducted by Singh et al. in the earliest days of the COVID-19 outbreak, six patients received allogeneic cardiosphere-derived cells after receiving an anti-IL-6 agent. The gene discussed is IL6; the disease is COVID-19.